866-997-4948(US-Canada Toll Free)

Rhabdomyosarcoma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Oncology

No. of Pages : 65 Pages


Global Markets Directs, \'Rhabdomyosarcoma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Rhabdomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Rhabdomyosarcoma.
  • A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Rhabdomyosarcoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rhabdomyosarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Rhabdomyosarcoma - Overview 8
Pipeline Products for Rhabdomyosarcoma - Comparative Analysis 9
Rhabdomyosarcoma - Therapeutics under Development by Companies 10
Rhabdomyosarcoma - Therapeutics under Investigation by Universities/Institutes 12
Rhabdomyosarcoma - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Rhabdomyosarcoma - Products under Development by Companies 15
Rhabdomyosarcoma - Products under Investigation by Universities/Institutes 16
Rhabdomyosarcoma - Companies Involved in Therapeutics Development 17
Shionogi & Co., Ltd. 17
Eli Lilly and Company 18
Daiichi Sankyo Company, Limited 19
Celgene Corporation 20
Arisaph Pharmaceuticals, Inc. 21
Vaccinex, Inc. 22
Merrimack Pharmaceuticals, Inc. 23
Neotropix, Inc. 24
Rhabdomyosarcoma - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Assessment by Therapeutic Class 35
Drug Profiles 37
cixutumumab - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
exatecan mesylate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
paclitaxel - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NTX-010 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
irinotecan sucrosofate liposomal - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Dendritic Cell Vaccine + [decitabine] + [imiquimod] - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Peptide Cocktail Vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VX-70 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
PX-916 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ARI-4175 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Rhabdomyosarcoma - Recent Pipeline Updates 55
Rhabdomyosarcoma - Dormant Projects 62
Rhabdomyosarcoma - Discontinued Products 63

Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Table


Number of Products under Development for Rhabdomyosarcoma, H2 2013 8
Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 16
Rhabdomyosarcoma - Pipeline by Shionogi & Co., Ltd., H2 2013 17
Rhabdomyosarcoma - Pipeline by Eli Lilly and Company, H2 2013 18
Rhabdomyosarcoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2013 19
Rhabdomyosarcoma - Pipeline by Celgene Corporation H2 2013 20
Rhabdomyosarcoma - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2013 21
Rhabdomyosarcoma - Pipeline by Vaccinex, Inc., H2 2013 22
Rhabdomyosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2013 23
Rhabdomyosarcoma - Pipeline by Neotropix, Inc., H2 2013 24
Assessment by Monotherapy Products, H2 2013 25
Assessment by Combination Products, H2 2013 26
Number of Products by Stage and Target, H2 2013 28
Number of Products by Stage and Mechanism of Action, H2 2013 30
Number of Products by Stage and Route of Administration, H2 2013 32
Number of Products by Stage and Molecule Type, H2 2013 34
Number of Products by Stage and Therapeutic Class, H2 2013 36
Rhabdomyosarcoma Therapeutics - Recent Pipeline Updates, H2 2013 55
Rhabdomyosarcoma - Dormant Projects, H2 2013 62
Rhabdomyosarcoma - Discontinued Products, H2 2013 63

List of Chart


Number of Products under Development for Rhabdomyosarcoma, H2 2013 8
Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 25
Number of Products by Top 10 Target, H2 2013 27
Number of Products by Stage and Top 10 Target, H2 2013 28
Number of Products by Top 10 Mechanism of Action, H2 2013 29
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 30
Number of Products by Top 10 Route of Administration, H2 2013 31
Number of Products by Stage and Top 10 Route of Administration, H2 2013 32
Number of Products by Top 10 Molecule Type, H2 2013 33
Number of Products by Stage and Top 10 Molecule Type, H2 2013 34
Number of Products by Top 10 Therapeutic Class, H2 2013 35
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 36

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *